Question: An angel investor is considering a portfolio of 8 biotech firms: 4 developing mRNA vaccines, 3 working on CRISPR therapies, and 1 focused on regenerative medicine. If the investor selects 4 firms at random, what is the probability that at least one firm from each research area is included? - Treasure Valley Movers

An Angel Investor’s Strategic Opportunity: Calculating Risk & Diversity in a Rapidly Evolving Biotech Landscape

In today’s dynamic biotech investment scene, a growing number of forward-thinking angels are analyzing portfolio diversity through the lens of innovation clusters—mRNA vaccines, CRISPR therapies, and regenerative medicine. With recent breakthroughs accelerating drug development and competitive funding landscape shifts, understanding which combinations of firms represent balanced, forward-looking strategies is essential. This question—what’s the chance that a randomly selected 4-firm portfolio includes at least one from each research area—taps into a critical intersection of science, market risk, and long-term returns.

---

Why This Question Matters: A Trend in Biotech Funding

Biotech investment across key scientific fronts has reached unprecedented attention. mRNA vaccines surged into global focus during the pandemic, now expanding beyond infectious diseases. Meanwhile, CRISPR’s precision gene editing and regenerative medicine’s potential to reverse tissue degeneration are reshaping therapeutic possibilities. With limited funding spots and rising competition, savvy investors increasingly seek portfolios that balance emerging technologies and established platforms. Understanding the statistical likelihood of selecting diverse innovators helps assess both opportunity and exposure—key to informed decision-making in this high-stakes field.

---

How the Selection Process Works
The scenario involves a portfolio of 8 biotech firms: 4 mRNA vaccine developers, 3 CRISPR therapy innovators, and 1 regenerative medicine firm. When an investor selects 4 firms at random from this group, what’s the probability that at least one woman’s health—or cell treatment—research area is represented? This is a classic combinatorics problem with real-world implications for risk diversification.

To calculate this probability:

• Total ways to choose 4 firms from 8: C(8,4) = 70
• Favorable outcomes: portfolios containing at least one firm from mRNA, CRISPR, and regenerative medicine each
• Instead of counting favorable cases directly, we compute complementary probability: subtract cases missing at least one category from total combinations, then divide by 70 to get final odds

Only 3 firms belong to regenerative medicine—limited diversity here—making coverage from all three areas especially meaningful.

---

Step-by-Step Probability Calculation

To determine the chance of including at least one firm from each research area in a 4-firm pick:

• C(8,4) = 70 total combinations
• Portfolios missing mRNA: choose 4 from 4 CRISPR + 1 regenerative (5 options): C(5,4) = 5
• Portfolios missing CRISPR: choose 4 from 4 mRNA